Log In
BCIQ
Print this Print this
 

EM801

  Manage Alerts
Collapse Summary General Information
Company Celgene Corp.
DescriptionT-cell bispecific antibody targeting tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17; CD269)
Molecular Target Tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA) (TNFRSF17) (CD269)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$600.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/30/2016

$600.0M

Undisclosed

0

Get a free BioCentury trial today